Palvella Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Palvella Therapeutics (PVLA).

Price Target Range — 7 Quarters

Analyst Consensus — 16 Analysts

1S.Buy

15Buy

Consensus RatingBuy# Analysts16Avg. Consensus PT$161Upside to Avg. PT+2.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 21, 2026	Stephens & Co.	Sudan Loganathan	Maintained	Overweight	$220
May 21, 2026	Chardan Capital	Geulah Livshits	Maintained	Buy	$240
May 12, 2026	Stephens & Co.	Sudan Loganathan	Initiate	Overweight	$220
Mar 31, 2026	Chardan Capital	Geulah Livshits	PT Raise	Buy	$210→$240
Mar 24, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$255→$270
Mar 16, 2026	Chardan Capital	Geulah Livshits	Maintained	Buy	$210
Feb 25, 2026	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$205→$250
Feb 25, 2026	BTIG	Jeet Mukherjee	PT Raise	Buy	$192→$215
Feb 24, 2026	Chardan Capital	Geulah Livshits	PT Raise	Buy	$174→$210
Feb 24, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$200→$255
Jan 29, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$192
Jan 16, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$192
Jan 7, 2026	Mizuho	Graig Suvannavejh	Initiate	Outperform	$205
Dec 16, 2025	Truist Securities	Danielle Brill	PT Raise	Buy	$105→$190
Dec 16, 2025	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$148→$204
Dec 16, 2025	TD Cowen	Ritu Baral	PT Raise	Buy	$97→$133
Dec 16, 2025	Chardan Capital	Geulah Livshits	PT Raise	Buy	$110→$174
Dec 15, 2025	BTIG	Jeet Mukherjee	PT Raise	Buy	$167→$192
Dec 15, 2025	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$190→$200
Dec 5, 2025	Clear Street	Kaveri Pohlman	Initiate	Buy	$200

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Stephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price Target

Stephens & Co. analyst Sudan Loganathan reiterates Palvella Therapeutics (NASDAQ:PVLA) with a Overweight and maintains $220 price target.

Benzinga Newsdesk

PRO
Stephens & Co. Initiates Coverage On Palvella Therapeutics with Overweight Rating, Announces Price Target of $220

Stephens & Co. analyst Sudan Loganathan initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Overweight rating and announces Price Target of $220.

Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $240

Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $210 to $240.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Raises Price Target to $270

HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $255 to $270.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Palvella Therapeutics, Raises Price Target to $250

Mizuho analyst Graig Suvannavejh maintains Palvella Therapeutics (NASDAQ:PVLA) with a Outperform and raises the price target from $205 to $250.

Benzinga Newsdesk

CAVA Group To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Wednesday

Avi Kapoor

Palvella Therapeutics Inc

Palvella Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Stephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price Target

PRO
Stephens & Co. Initiates Coverage On Palvella Therapeutics with Overweight Rating, Announces Price Target of $220

PRO
Chardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $240

PRO
HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Raises Price Target to $270

PRO
Mizuho Maintains Outperform on Palvella Therapeutics, Raises Price Target to $250

CAVA Group To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Wednesday

People Also Watch

People Also Watch

Palvella Therapeutics Inc

Palvella Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROStephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price Target

PROStephens & Co. Initiates Coverage On Palvella Therapeutics with Overweight Rating, Announces Price Target of $220

PROChardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $240

PROHC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Raises Price Target to $270

PROMizuho Maintains Outperform on Palvella Therapeutics, Raises Price Target to $250

CAVA Group To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Wednesday

People Also Watch

People Also Watch

PRO
Stephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price Target

PRO
Stephens & Co. Initiates Coverage On Palvella Therapeutics with Overweight Rating, Announces Price Target of $220

PRO
Chardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $240

PRO
HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Raises Price Target to $270

PRO
Mizuho Maintains Outperform on Palvella Therapeutics, Raises Price Target to $250